Journal: Biochemistry and Biophysics Reports

Article Title: Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir

doi: 10.1016/j.bbrep.2022.101283

Figure Lengend Snippet: (A) Compounds structure. Compounds 27a, 27b, 9f, 19a, 31b and 31d are our recently developed microtubule inhibitors which target the colchicine binding site. Daclatasvir and ledipasvir are clinically used drugs which target HCV NS5A. (B) Immunofluorescence images of FFU assays to determine infectivity titer. Huh7.5.1 cells were infected by various dilutions of cell culture medium (a, mock infected), JFH-1 D183 virus stock (b) and newly produced viral supernatant (c) separately. After 72 h infection, Huh7.5.1 cells were fixed and stained for NS5A (red) and nuclei (blue). Clusters of 2–50 NS5A positive cells were considered as foci. (C) Quantitative real time PCR (qRT-PCR) results (left panel) and toxicity assay results (right panel) of daclatasvir and compound 9f at 24 h and 48 h. HCV RNA was relatively quantified by normalization to untreated control. GAPDH was used as housekeeping gene to guarantee the same base level. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Ledipasvir and daclatasvir were purchased from Fisher Scientific.

Techniques: Binding Assay, Immunofluorescence, Infection, Cell Culture, Virus, Produced, Staining, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Control

Journal: Biochemistry and Biophysics Reports

Article Title: Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir

doi: 10.1016/j.bbrep.2022.101283

Figure Lengend Snippet: Inhibitory activities and toxicities of microtubule inhibitors, daclatasvir and ledipasvir in BM45-Feo replicon cells.

Article Snippet: Ledipasvir and daclatasvir were purchased from Fisher Scientific.

Techniques: